The biotechnology company said the FDA approved the biologics license application for Nuvaxovid to prevent Covid-19 in adults ages 65 and up and individuals ages 12 through 64 who have at least one underlying condition that puts them at high risk for severe outcomes from the coronavirus.

In the options pits, NVAX has already seen quadruple the overall options volume it typically sees in an entire session, with 57,000 calls and 13,000 puts exchanged so far. The weekly 5/23 9-strike call is the most active, with new positions opening there.